News
Opening up about drug pricing decisions is not optional for biopharma anymore. For the sake of credibility, companies should embrace it.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Bristol Myers Squibb, GSK and Merck are contributing drug ingredients as part of their deals with the White House but are keeping many of the terms of their agreements private.
Some 200 rare disease therapies are at risk of losing eligibility for a pediatric priority review voucher, a recent analysis by the Rare Disease Company Coalition shows. That could mean $4 billion in missed revenue for already cash-strapped biotechs.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Phacilitate’s annual event dawns as cell and gene therapies reach a new tipping point: the science has hit new heights just as regulatory and government policies spark momentum and frustration.
THE LATEST
In this webinar, we discuss how to create policies that are fair for both remote and local workers; vaccination policies; travel policies; communication strategies and managing employee relations in regards to these changes.
BioSpace was thrilled to host a virtual panel discussion to hear how workplaces can improve their D&I strategies and help organizations thrive. We heard insightful advice from panelists from Amgen, Intellia Therapeutics, Obsidian Therapeutics, Omega Therapeutics and Athira Pharma.
BioSpace was delighted to host a virtual panel discussion to hear how workplaces can prepare for a return to the office, and how to approach new policies related to Covid-19, mental health support, remote work culture, and more. This was a thoughtful discussion with insights from CalciMedica, Sutro Biopharma, Affinity Empowering, Axogen and Chiasma.
How can life science workplaces improve not only diversity but create enduring inclusivity that not only empowers employees but fosters a culture of success and mutual trust?
Though data became an issue in two separate meetings, the FDA’s Oncologic Drugs Advisory Committee made a potentially precedent-setting decision by voting in favor of US WorldMeds’ neuroblastoma treatment.
Following a Phase III failure and the departure of its CEO, Mirati Therapeutics is rumored to be engaged in acquisition discussions with French pharma giant Sanofi, according to Bloomberg.
After finally getting the green light from the Federal Trade Commission last month, Amgen has completed the buyout and expects to provide updated fiscal year 2023 guidance during its third-quarter earnings call.
Keytruda’s winning streak in bladder continues with positive data from the Phase III AMBASSADOR study, showing significantly better disease-free survival in muscle-invasive urothelial carcinoma.
Data from a confirmatory study could not be reliably interpreted, according to the Oncologic Drugs Advisory Committee, which voted against Amgen’s request for full approval of its G12C KRAS inhibitor.
In this job market report we’re reviewing life sciences job market movement in Q3 and what to expect for Q4 and beyond.